Capturing the paradigm shift in HIV treatment: Changing attitudes in the choice of combination antiretroviral drugs by high HIV caseload Australian GPs (1996-1997)

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 12, Issue 1, 2000, Pages 41-47

  Smith, Don ^a   Goggin, L ^a   Meldrum, H ^a   Phillips, S ^b   Russell, D ^c   Bloch, M ^d   Bodsworth, N J ^e   Roth, N ^f   Law, M G ^g  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b AMFAC Pharmaceutical   (Australia)

^c Carlton Clinic   (Australia)

^d Holdsworth House General Practice   (Australia)

^e Taylor Square Private Clinic ^*  (Australia)

^f Prahran Market Clinic   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; AUSTRALIA; DRUG CHOICE; DRUG EFFICACY; DRUG PREFERENCE; GENERAL PRACTITIONER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NORMAL HUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; WORKLOAD;

ANTI-HIV AGENTS; AUSTRALIA; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; HIV INFECTIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 0033964895     PISSN: 09540121     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540120047459     Document Type: Article

References (19)

1. Australian HIV Surveillance Report, 13(3), July 1997.
2. Caesar Coordinating Committee (1997). Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: the Caesar trial. The Lancet, 349, 1413-1421.
3. Carr, A., Samaras, K., Burton, S., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 121, 15-18.
4. Coffin, J.M. (1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science, 267, 483-489.
5. Delta Coordinating Committee (1996). Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. The Lancet, 348, 283-291.
6. Feinberg, M. (1997) Hidden dangers of incompletely suppressive antiviral therapy. The Lancet, 349, 1408-1409.
7. Fischl, M.A., Stanley, K., Collier, A.C. et al. (1995). Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Annals of Internal Medicine, 122, 24-32.
8. Gulick, R.M., Mellor, J.W., Havlir, D., et al. (1997). Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine, 337, 734-739.
9. Hammer, S.M., Katzenstein, D.A., Hughes, M.D., et al. (1996). A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. New England Journal of Medicine, 335, 1081-1090.
10. Hammer, S.M., Squires, K.E., Hughes, M.D., et al. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine, 337, 725-733.
11. Ho, D.D., Neumann, A.U., Perelson, A.S., et al. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126.
12. Kuhn, T.S. (1996). The structure of scientific revolutions, 3rd edition. Chicago: University of Chicago Press.
13. Montaner, J.S.G., Reiss, P., Cooper, D., et al. (1998). A randomised, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. Journal of the American Medical Association, 279, 930-937.
14. 3. Abstract 294, XI International Conference on AIDS, Vancouver, July.
15. Perelson, A.S., Essunger, P., Cao, Y., et al. (1997) Decay characteristics of HIV-1 infected compartments during combination therapy. Nature, 387, 123-124.
16. Rozenbaum, W. & The Avanti Study Group (1997). A randomized, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs AZT/3TC/loviride in antiretroviral naive patients. Abstract 368, 4th Conference on Retroviruses and Opportunistic Infections, Washington DC, January.
17. Salgo, M.P., Beattie, D., Bragman, K., et al. (1996). Saquinavir (invirase, SQV) vs Hivid (zalcitabine, ddC) vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (zidovudine, ZDV). Abstract 410, XI International Conference on AIDS, Vancouver, July.
18. Schooley, R.T., Ramirez-Ronda, C., Lange, J.M.A., et al. (1996). Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Journal of Infectious Diseases, 174, 1354-1366.
19. Wei, X., Ghosh, S.K., Taylor, M.E., et al. (1995). Viral dynamics in human immunodeficiency virus type-1 infection. Nature, 373, 117-122.